PT Diagnos Laboratorium Utama Tbk (DGNS.JK)
IDR 210.0
(0.0%)
IDR 210.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 13.18 Billion | -6.01 Billion | 58.87 Billion | 26.22 Billion | 11.19 Billion | 8.46 Billion |
| Net Income | -13.65 Billion | 12.66 Billion | 64.3 Billion | 52.68 Billion | 9.27 Billion | 9.26 Billion |
| Depreciation & Amortization | 14.63 Billion | 13.23 Billion | 7.56 Billion | 3.84 Billion | 2.25 Billion | 409.37 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | 12.2 Billion | -5.44 Billion | 2.13 Billion | -22.61 Billion | 4.17 Billion | -387.28 Million |
| Investing Cash Flow | -42.38 Billion | -17.55 Billion | -75.56 Billion | -8.15 Billion | -29.23 Billion | -6.46 Billion |
| Investments in PPE | -38.32 Billion | -34.85 Billion | -67.84 Billion | -5.86 Billion | -2.78 Billion | -3.83 Billion |
| Acquisitions | 649.65 Million | - | - | - | - | - |
| Investment purchases | -4.5 Billion | -8.05 Billion | - | - | - | - |
| Sales/Maturities of investments | 4.06 Billion | - | - | - | - | - |
| Other Investing Activities | -4.06 Billion | 25.35 Billion | -7.72 Billion | -2.28 Billion | -26.45 Billion | -2.62 Billion |
| Financing Cash Flow | 11.43 Billion | 6.85 Billion | 44.87 Billion | -2.93 Billion | 17.89 Billion | -1.77 Billion |
| Debt repayment | -11.43 Billion | -10.77 Billion | -4.25 Billion | -369.84 Million | -5.09 Billion | -112.8 Million |
| Dividends payments | - | - | -6 Billion | - | - | - |
| Common Stock Repurchased | - | - | -646.26 Million | - | - | - |
| Common Stock Issuance | - | - | 49.47 Billion | - | 24.75 Billion | - |
| Other Financing Activities | -2.04 Billion | -714.59 Million | 6.29 Billion | -30.42 Billion | 24.75 Billion | -1.65 Billion |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 28.01 Billion | 44.71 Billion | 16.53 Billion | 1.39 Billion | 1.53 Billion | 1.3 Billion |
| Cash at end of period | 10.24 Billion | 28.01 Billion | 44.71 Billion | 16.53 Billion | 1.39 Billion | 1.53 Billion |
| Capital Expenditure | -38.32 Billion | -34.85 Billion | -67.84 Billion | -5.86 Billion | -2.78 Billion | -3.83 Billion |
| Effect of forex changes on cash | - | - | 1.00 | -1.00 | - | - |
| Net cash flow / Change in cash | -17.76 Billion | -16.7 Billion | 28.18 Billion | 15.14 Billion | -143.93 Million | 233.89 Million |
| Free Cash Flow | -25.14 Billion | -40.86 Billion | -8.96 Billion | 20.36 Billion | 8.41 Billion | 4.63 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 940.04 Million | 217.84 Million | -3 Billion | -13.65 Billion | -2.91 Billion | -4.27 Billion |
| Depreciation & Amortization | 3.68 Billion | 3.64 Billion | 3.5 Billion | 14.63 Billion | 3.64 Billion | 3.71 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | 6.06 Billion | 11.94 Billion | 6.59 Billion | 41.47 Billion | 13.01 Billion | 7.91 Billion |
| Investing Cash Flow | -4.46 Billion | -11.66 Billion | -8.6 Billion | -42.38 Billion | -9.87 Billion | -7.7 Billion |
| Investments in PPE | -4.58 Billion | -11.66 Billion | -8.61 Billion | -38.53 Billion | -9.87 Billion | -7.7 Billion |
| Acquisitions | 117.11 Million | - | 9.78 Million | 649.65 Million | -292.04 Thousand | 800 Thousand |
| Investment purchases | - | - | - | -4.5 Billion | - | - |
| Sales/Maturities of investments | - | - | - | 4.06 Billion | - | - |
| Other Investing Activities | - | -1.66 Billion | 9.78 Million | -4.06 Billion | -8.29 Million | -199.2 Million |
| Financing Cash Flow | 2.78 Billion | -469.22 Million | -933.77 Million | 11.43 Billion | 9.9 Billion | -1.05 Billion |
| Debt repayment | -3.9 Billion | -151.95 Million | -17.11 Billion | -13.48 Billion | -7.28 Billion | -454.19 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.12 Billion | -151.95 Million | -933.77 Million | -2.04 Billion | 9.9 Billion | -1.05 Billion |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 6.61 Billion | 10.24 Billion | 19.69 Billion | 28.01 Billion | 13.22 Billion | 22.06 Billion |
| Cash at end of period | 8.26 Billion | 6.61 Billion | 10.24 Billion | 10.24 Billion | 19.69 Billion | 13.22 Billion |
| Capital Expenditure | -4.58 Billion | -11.66 Billion | -8.61 Billion | -38.53 Billion | -9.87 Billion | -7.7 Billion |
| Effect of forex changes on cash | - | - | - | - | - | -1.00 |
| Net cash flow / Change in cash | 1.64 Billion | -3.62 Billion | -9.45 Billion | -17.76 Billion | 6.47 Billion | -8.84 Billion |
| Free Cash Flow | -1.25 Billion | -3.15 Billion | -8.52 Billion | -25.34 Billion | -3.42 Billion | -7.78 Billion |
NYR
RBD
JBI
LPA
MCD
LUVU